Editors’ note: This animal study investigating the effects of Lactobacillus rhamnosus, a strain of probiotic bacteria, on ulcers of the stomach lining of rats demonstrated that bacteria placed directly into the stomach significantly and according to dose reduced gastric ulcer size. If the results of this animal research are reproduced in humans, it would demonstrate that probiotics may hasten recovery for people suffering from stomach ulcers. The bacteria did not affect the function of normal gastric mucosa but normalized those with abnormal changes during ulceration. Read More »
The Celiac Disease Center at Columbia University is starting a research study to assess the knowledge of chefs and the general public about celiac disease. They are also looking at people who follow the gluten-free diet (because of celiac disease or gluten sensitivity) and whether their quality of life with respect to restaurant eating is affected because of the diet.
Plaza Research is currently recruiting men and women ages 18 and older who have been diagnosed with Celiac Disease to participate in a paid telephone discussion on the topic of Celiac Disease. The phone interviews are taking place on April 15th and April 27th, 2010 and will last approximately 1 hour in length. All participants will receive $50.00 for their time and opinions.
If you or anyone you know may be interested, please click on the link below to complete the online application for the study. All responses will be reviewed and qualified applications will be called back on first come first served basis until all seats are filled.
Author Information: Jennifer D. Harris, Atlanta, GA
Jennifer D. Harris, http://www.jenniferglutenfreeingeorgia.blogspot.com/
Gluten-Free Product Specialist, Return to Eden.
Program Chair, Atlanta Metro Celiacs, www.atlantametroceliacs.org
A team of business school students from Boston College invites the gluten-free community to participate in an important market research survey. The goal is to learn more about consumers with specific dietary needs. The results of the survey will be used to assist in offering detailed recommendations about how to better support the community with unique, high-quality, gluten-free foods. This survey is intended for market research purposes only. Your opinion will be kept confidential. All results will be reported in the aggregate and not as individual entries. Read More »
According to the Centers for Disease Control, as of 2006, 33.1% of women were choosing to exclusively breastfeed their newborn from 0-3 months of age. At the one-year mark, only 22.7% of women were still breastfeeding their baby (non-exclusively).
The American Academy of Pediatrics Committee, the World Health Organization (WHO), the Canadian Pediatric Society, the Pediatric Society of New Zealand, and other similar organizations in various countries worldwide have all made statements on infant feeding and the appropriate time to introduce solid foods into a baby’s diet. The current consensus is that solid food should not be introduced until at least the age of 4-6 months, if not later. Read More »
THURSDAY, July 24 (HealthDay News) — Researchers believe they have finally answered a basic question about the cause of celiac disease — where in the body does the wheat protein gluten enter one’s system?
A study published in the July issue of Gastroenterology identifies the CXCR3 receptor in the intestine as a gluten gateway. When people with celiac disease eat gluten, the protein triggers their immune system to attack the body, causing a wide range of serious health problems.
“This is a scientific question that had never been answered before,” Dr. Alessio Fasano, medical director of the Center for Celiac Research at the University of Maryland School of Medicine, said in an university news release. “It is not only significant in the basic science of autoimmune disorders such as celiac disease, but in therapeutic approaches for the future. This opens a new scientific paradigm for the study of immunity.”
The research team found that gliadin, the part of gluten that causes the most trouble for those with celiac disease, binds to the CXCR3 receptor. This results in the release of zonulin, a human protein that lowers the intestinal barrier to make it more permeable. While this effect is temporary in most people, the barrier stays down for long periods of time in people with celiac disease, causing disruption in the body’s system.
The finding may help in research on the cause and treatment for other autoimmune diseases, Fasano said. People with type 1 diabetes and multiple sclerosis may experience a similar condition in which offending antigens enter the body through this gateway in the intestines.
“For the first time, we have evidence of how the foreign antigen gains access to the body, causing the autoimmune response,” said Fasano, who is also a pediatric gastroenterologist at the University of Maryland Medical Center. “Further study is needed, but this could allow us to intervene before the zonulin is either released or activated, preventing the immune response altogether.”
Dr. Joseph Murray of the Mayo Clinic explains his landmark study that tested blood samples from 50 years ago and compared them to people of the same ages today. The results: 1. Celiac disease is 5 times more prevalent than it was 50 years ago, 2. People with untreated celiac disease are 4 times more likely to die prematurely than the general population. This breaking information shows us that the rate of celiac disease is rising and people must be identified and diagnosed to insure good health. – John Libonati, Editor. Glutenfreeworks.com
Alba Therapeutics Corporation announced today that for the first time, a European patient with active celiac disease has been enrolled in its clinical trial to investigate a treatment for the disease. Alba has enrolled and randomized the newly diagnosed patient from Spain in an eight-week Phase IIb trial with oral larazotide acetate, a tight junction regulator, for the treatment of patients with active celiac disease (CD). The global multi-center, randomized, double-blind, placebo-controlled study will evaluate the clinical and histological efficacy, safety and tolerability of larazotide acetate in 106 active CD subjects adhering to a gluten-free diet, while assessing improvement in the clinical signs and symptoms of celiac disease.
(1) Green, P, and Cellier, C, Review Article, Medical Progress, Celiac Disease, N ENGL J MED 2007;357:1731-43
For more information about Alba’s clinical trials, please visit the www.clinicaltrials.gov web site and search for Alba Therapeutics.
Media: Mariesa Kemble Sam Brown Communications 608-850-4745 email@example.com Corporate: Wendy Perrow, MBA Alba Therapeutics Corporation 410-878-9850 firstname.lastname@example.org http://www.albatherapeutics.com
---------------------- Author Information: John Libonati, Philadelphia, PA Publisher, Glutenfreeworks.com. Editor & Publisher, Recognizing Celiac Disease. John can be reached by e-mail here.
The research below further supports the links demonstrated between celiac disease and psoriasis as noted in the book “Recognizing Celiac Disease.” (www.recognizingceliacdisease.com) Although not the focus of this study, the link could be a genetic sensitivity to gluten itself, considering the resolution of symptoms seen by people with psoriasis who go on a gluten-free diet. In addition, the other disorders, diabetes type 1 and arthritis have been linked to celiac disease/gluten sensitivity reactions. – John Libonati, Glutenfreeworks.com
Psoriasis: 7 New Genetic Clues
Newly Discovered Genetic Variations May Make Psoriasis More Likely, Study Shows
By Miranda Hitti
WebMD Medical NewsReviewed by Louise Chang, MDApril 3, 2008 — Scientists have discovered seven genetic variations linked to psoriasis.
If confirmed in other studies, those gene variants may make good targets for new psoriasis drugs, note the researchers, who included Anne Bowcock, PhD, genetics professor at Washington University School of Medicine in St. Louis.
“Common diseases like psoriasis are incredibly complex at the genetic level,” Bowcock says in a news release. “Our research shows that small but common DNA differences are important in the development of psoriasis. Although each variation makes only a small contribution to the disease, patients usually have a number of different genetic variations that increases their risk of psoriasis and psoriatic arthritis.”
Bowcock’s team compared DNA from 223 psoriasis patients (including 91 with psoriatic arthritis) and 519 people without psoriasis, and also from two other large groups of people with and without psoriasis.
Through those comparisons, the researchers identified seven genetic variations linked to psoriasis and psoriatic arthritis and confirmed other variations already linked to psoriasis.
One of the newly discovered variants is in a genetic region tied to four other autoimmune diseases: celiac disease, type 1 diabetes, Grave’s disease, and rheumatoid arthritis.
Further studies are needed to confirm the findings, Bowcock and colleagues note in the April 4 online edition of Public Library of Science Genetics.
View Article Sources
Liu, Y. Public Library of Science Genetics, April 4, 2008; online edition.
News release, Public Library of Science.
© 2008 WebMD, LLC. All rights reserved.
Contact: Sally Webster
Queen Mary, University of London
Scientists who last year identified a new genetic risk factor for coeliac disease, have, following continued research, discovered an additional seven gene regions implicated in causing the condition. The team, lead by David van Heel, Professor of Gastrointestinal Genetics at Barts and The London School of Medicine and Dentistry, have further demonstrated that of the nine coeliac gene regions now know, four of these are also predisposing factors for type 1 diabetes. Their research sheds light not only on the nature of coeliac disease, but on the common origins of both diseases. It is published online today (2 March 2008) in Nature Genetics.
Professor van Heel and his team, including collaborators from Ireland, the Netherlands, and the Wellcome Trust Sanger Institute, first performed a genome wide association study in coeliac disease. Genetic markers across the genome were compared in coeliac disease subjects versus healthy controls. They then assessed around 1,000 of the strongest markers in a further ~ 5,000 samples. Their results identified seven new risk regions, six of which harbour important genes critical in the control of immune responses, highlighting their significance in the development of the disease.
Coeliac disease is common in the West, afflicting around 1 per cent of the population. It is an immune-mediated disease, triggered by intolerance to gluten (a protein found in wheat, barley and rye containing foods), that prevents normal digestion and absorption of nutrients. If undetected it can lead to a number of often severe problems among them anaemia, poor bone health, fatigue and weight loss. Currently only a restricted diet can diminish symptoms.
Professor van Heel said: “So far our findings explain nearly half of the heritability of coeliac disease – now studies with many more samples from individuals with coeliac disease are needed to identify the precise causal genetic variants from each region, and understand how these influence biological processes.”
The research was funded by Coeliac UK and The Wellcome Trust. Coeliac disease case studies are available for interview from Coeliac UK upon request.
The paper, ‘Newly identified genetic risk variant for celiac disease related to the immune response’ is published online, on 2 March 2008, in Nature Genetics.
For case studies contact:
Tel: 020 8399 7478
Mobile: 07952 071014
Notes to editors:
Barts and The London School of Medicine and Dentistry offers international levels of excellence in research and teaching while serving a population of unrivalled diversity amongst which cases of diabetes, hypertension, heart disease, TB, oral disease and cancers are prevalent, within east London and the wider Thames Gateway. Through partnership with our linked trusts, notably Barts and The London NHS Trust, and our associated University Hospital trusts – Homerton, Newham, Whipps Cross and Queen’s – the School’s research and teaching is informed by an exceptionally wide ranging and stimulating clinical environment.
At the heart of the School’s mission lies world class research, the result of a focused programme of recruitment of leading research groups from the UK and abroad and a £100 million investment in state-of-the-art facilities. Research is focused on translational research, cancer, cardiology, clinical pharmacology, inflammation, infectious diseases, stem cells, dermatology, gastroenterology, haematology, diabetes, neuroscience, surgery and dentistry.
The School is nationally and internationally recognised for research in these areas, reflected in the £40 million it attracts annually in research income. Its fundamental mission, with its partner NHS Trusts, and other partner organisations such as CRUK, is to ensure that that the best possible clinical service is underpinned by the very latest developments in scientific and clinical teaching, training and research.